Alliance Pharma completed the acquisition of Biogix for $110m.

Alliance Pharma, an international healthcare group, completed the acquisition of Biogix, the US-based consumer healthcare company, for $110m. "As 2020 draws to a close, I am very pleased to be announcing the successful completion of the Biogix acquisition, a substantial and strategically important acquisition for Alliance, which increases our presence in the US and in consumer healthcare. As an established, clinically evidenced brand with significant sales and good growth potential, in a growing market, Amberen fits perfectly with our strategy of acquiring established consumer healthcare brands in territories where we already have a presence," Peter Butterfield, Alliance Chief Executive Officer.